• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin.
【24h】

Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin.

机译：非那雄胺与特拉唑嗪之间的药代动力学相互作用，但非那雄胺与多沙唑嗪之间没有药代动力学相互作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The alpha 1-adrenoceptor antagonists doxazosin and terazosin and the 5 alpha-reductase inhibitor finasteride are used in the treatment of benign prostatic hyperplasia. The aim of this study was to assess the potential pharmacokinetic interaction of doxazosin or terazosin when coadministered with finasteride. This was a randomized, placebo-controlled, multi-center study. Ninety healthy men were assigned to one of six treatment groups: doxazosin; doxazosin plus finasteride; terazosin; terazosin plus finasteride; placebo; and placebo plus finasteride. Plasma concentrations, maximum plasma concentration (Cmax), time to maximum concentration (tmax), and area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24) of doxazosin, terazosin, and finasteride were determined. Ratios of Cmax and AUC for doxazosin and terazosin were not significantly altered by coadministration with finasteride. The Cmax and AUC0-24 of finasteride were not significantly altered by coadministration with doxazosin. However, Cmax and AUC0-24 of finasteride were significantly higher after coadministration with terazosin. There is no statistically significant pharmacokinetic interaction between finasteride and doxazosin; however, there is a statistically significant interaction between finasteride and terazosin, which affects the pharmacokinetics of finasteride but not those of terazosin. The clinical significance of this interaction remains to be determined.
机译：α1-肾上腺素能受体拮抗剂多沙唑嗪和特拉唑嗪和5α-还原酶抑制剂非那雄胺用于治疗前列腺增生。这项研究的目的是评估与非那雄胺合用时多沙唑嗪或特拉唑嗪的潜在药代动力学相互作用。这是一项随机，安慰剂对照的多中心研究。 90名健康男性被分配到六个治疗组之一：多沙唑嗪;多沙唑嗪加非那雄胺;特拉唑嗪特拉唑嗪加非那雄胺;安慰剂;和安慰剂加非那雄胺。确定了多沙唑嗪，特拉唑嗪和非那雄胺的血浆浓度，最大血浆浓度（Cmax），达到最大浓度的时间（tmax）以及血浆浓度-时间曲线下从0到24小时的面积（AUC0-24）。与非那雄胺合用时，多沙唑嗪和特拉唑嗪的Cmax和AUC比率没有明显改变。与多沙唑嗪合用时，非那雄胺的Cmax和AUC0-24没有明显改变。然而，与特拉唑嗪合用后，非那雄胺的Cmax和AUC0-24明显更高。非那雄胺与多沙唑嗪之间无统计学意义的药代动力学相互作用。然而，非那雄胺与特拉唑嗪之间存在统计学上显着的相互作用，这会影响非那雄胺的药代动力学，但不会影响特拉唑嗪的药代动力学。这种相互作用的临床意义尚待确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号